FoundationOne™ Test Registry Study (FMI Registry)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Foundation Medicine
Sponsor:
Collaborator:
Quintiles
Information provided by (Responsible Party):
Foundation Medicine
ClinicalTrials.gov Identifier:
NCT01851213
First received: May 6, 2013
Last updated: May 15, 2013
Last verified: May 2013
  Purpose

This study is a prospective, multicenter, observational study to characterize utilization patterns of the FoundationOne™ test by oncologists under conditions of routine clinical practice in the US. The study will also examine impact of test results on subsequent clinical decisions regarding choice of therapy. The planned duration of the study is at least 2 years with 1 year for patient recruitment and a minimum 1-year follow-up period for each patient. Any patient for whom the treating physician has ordered a FoundationOne™ test and a report is delivered is eligible for participation on the study. Eligible patients from participating sites will be enrolled sequentially during the 1-year enrollment period. Sites will be required to maintain an enrollment log of all patients for whom the FoundationOne™ test has been ordered and document patient disposition and reasons for non-participation. All treatment decisions and clinical assessment will be made at the discretion of the treating physician per usual care and are not mandated by study design or protocol. Informed consent will be obtained from eligible patients prior to study entry.


Condition
Cancer
Neoplasm Metastasis
Tumor

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: A Prospective Observational Study to Examine, in Routine Clinical Practice in the US, Practice Patterns and Impact on Clinical Decision Making Associated With the FoundationOne™ Next Generation Sequencing (NGS) Test

Resource links provided by NLM:


Further study details as provided by Foundation Medicine:

Primary Outcome Measures:
  • Composite characterization of current real-world practice patterns in the use of the FoundationOne™ test and the effect of the FoundationOne™ test on clinical decision making across the US [ Time Frame: Minimum 1 year follow-up ] [ Designated as safety issue: No ]

    Characterization of practice patterns for the use of the test described by:

    • Provider and site characteristics of patients receiving the FoundationOne test
    • Socio-demographic and clinical characteristics of patients receiving the FoundationOne test

    Examination of the effect of the test on clinical decision making by describing:

    • Subsequent treatment patterns for patients after receipt of test results
    • Clinician report outcomes regarding how test results guided clinical decision making


Secondary Outcome Measures:
  • Exploratory endpoints describing clinical outcomes in the study population [ Time Frame: Minimum 1 year follow-up ] [ Designated as safety issue: No ]
    • Overall survival
    • 1-year survival
    • Overall progression-free survival (PFS)


Estimated Enrollment: 500
Study Start Date: March 2013
Estimated Study Completion Date: March 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
FoundationOne™ Test Ordered
Patients for whom a FoundationOne™ test was ordered and a report is delivered.

Detailed Description:

Molecular testing of tumors, using techniques such as next-generation sequencing (NGS), facilitates an individualized approach to cancer treatment by sub-classifying diseases on an individual basis. Physicians can utilize an in depth understanding of disease at a molecular level to optimize therapy by selecting the most appropriate drugs and therapeutic targets. Genomic profiling has identified multiple genomic aberrations that are predictive markers for treatment response with targeted therapeutics.

FoundationOne™ is a commercially available molecular diagnostics test, for all solid tumor types, that analyzes routine clinical specimens for somatic alterations in relevant cancer-related genes. This validated in vitro diagnostic test, is performed in a single Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) approved laboratory at Foundation Medicine, Inc. It provides individualized, potentially actionable information regarding a patient's molecular cancer subtype that can be used by physicians to tailor treatment options.

With the recent commercial availability of the FoundationOne™ test, knowledge gaps exist regarding practice patterns associated with the use of this test in routine clinical practice and the impact of this test on clinical decision making. There is limited information regarding physician and patient characteristics that determine which patients receive the test, rationale for patient selection, and how physicians interpret and use the test results. Findings from this study will help to optimize patient selection and maximize the clinical impact of the test in terms of guiding therapy.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

This Pilot Study will aim to enroll approximately 500 patients from a total of 40 oncology centers in the US over a 1-year time period. Any patient for whom the treating physician has ordered the FoundationOne test is eligible for inclusion in the study. In order to capture real-world treatment patterns, site recruitment will aim to include approximately 80% of sites (and 80% of patients) from the community oncology setting. Enrollment will be competitive and each site will be capped at a maximum of 15 patients.

Criteria

Inclusion Criteria:

The FoundationOne test was ordered by the treating physician under routine clinical practice

  • Age ≥ 18 years
  • Patient willing and able to provide informed consent
  • Informed consent date is at least one day prior to the FoundationOne test report date

Exclusion Criteria:

There are no exclusion criteria for this study

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01851213

Contacts
Contact: Norma Palma, PhD 6174182200 npalma@foundationmedicine.com

Locations
United States, Washington
Evergreen Hematology/Oncology Recruiting
Spokane, Washington, United States, 99218
Principal Investigator: Stephen Anthony, MD         
Sponsors and Collaborators
Foundation Medicine
Quintiles
Investigators
Principal Investigator: Gary Palmer, MD Sr VP Medical Afairs
  More Information

No publications provided

Responsible Party: Foundation Medicine
ClinicalTrials.gov Identifier: NCT01851213     History of Changes
Other Study ID Numbers: FMI-001-NGS-500
Study First Received: May 6, 2013
Last Updated: May 15, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Foundation Medicine:
genomics
cancer
registry
neoplasm metastasis

Additional relevant MeSH terms:
Neoplasms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes

ClinicalTrials.gov processed this record on September 18, 2014